| Author | Pinto, Paolla Beatriz de Almeida | |
| Author | Timis, Julia | |
| Author | Chuensirikulchai, Kantinan | |
| Author | Qin, Hui Li | |
| Author | Hsueh, Han Lu | |
| Author | Maule, Erin | |
| Author | Nguyen, Michael | |
| Author | Alves, Rúbens Prince dos Santos | |
| Author | Sosa Batiz, Fernanda Ana | |
| Author | Valentine, Kristen | |
| Author | Landeras Bueno, Sara | |
| Author | Kim, Kenneth | |
| Author | Hastie, Kathryn | |
| Author | Saphire, Erica Ollmann | |
| Author | Alves, Ada Maria de Barcelos | |
| Author | Ngono, Annie Elong | |
| Author | Shresta, Sujan | |
| Access date | 2024-12-30T12:01:56Z | |
| Available date | 2024-12-30T12:01:56Z | |
| Document date | 2024 | |
| Citation | PINTO, Paolla Beatriz de Almeida et al. Co-immunization with spike and nucleocapsid based DNA vaccines for long-term protective immunity against SARS-CoV-2 Omicron. npj Vaccines, v. 9, n. 252, p. 1-15, 19 Dec. 2024. | |
| ISSN | 2059-0105 | |
| URI | https://www.arca.fiocruz.br/handle/icict/67823 | |
| Description | Produção científica do Laboratório de Biotecnologia e Fisiologia de Infecções Virais. | pt_BR |
| Sponsorship | This study was supported by the Coordination of Improvement of Higher Education Personnel (CAPES) from the Oswaldo Cruz Institute (IOC-Fiocruz), grant 88887.472772/2019-00 and 88887.583319/2020-00 (Paolla Beatriz Almeida Pinto) and NIH U19 AI142790-02S1, the GHR Foundation, and the Overton family (Sujan Shresta and Erica Ollmann Saphire), the Arvin Gottleib Foundation and the Prebys Foundation (to Sujan Shresta). | |
| Language | eng | en_US |
| Publisher | Nature Research | |
| Rights | open access | |
| Title | Co-immunization with spike and nucleocapsid based DNA vaccines for long-term protective immunity against SARS-CoV-2 Omicron | en_US |
| Type | Article | |
| DOI | 10.1038/s41541-024-01043-3 | |
| Abstract | The continuing evolution of SARS-CoV-2 variants challenges the durability of existing spike (S)-based COVID-19 vaccines. We hypothesized that vaccines composed of both S and nucleocapsid (N) antigens would increase the durability of protection by strengthening and broadening cellular immunity compared with S-based vaccines. To test this, we examined the immunogenicity and efficacy of wild-type SARS-CoV-2 S- and N-based DNA vaccines administered individually or together to K18-hACE2 mice. S, N, and S + N vaccines all elicited polyfunctional CD4⁺ and CD8⁺ T cell responses and provided short-term cross-protection against Beta and Omicron BA.2 variants, but only co-immunization with S + N vaccines provided long-term protection against Omicron BA.2. Depletion of CD4⁺ and CD8⁺ T cells reduced the long-term efficacy, demonstrating a crucial role for T cells in the durability of protection. These findings underscore the potential to enhance long-lived protection against SARS-CoV-2 variants by combining S and N antigens in next-generation COVID-19 vaccines. | en_US |
| Affilliation | La Jolla Institute for Immunology. Center for Vaccine Innovation. San Diego, CA, USA / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Biotecnologia e Fisiologia de Infecções Virais. Rio de Janeiro, RJ, Brasil. | |
| Affilliation | La Jolla Institute for Immunology. Center for Vaccine Innovation. San Diego, CA, USA. | |
| Affilliation | Chiang Mai University. Faculty of Medicine. Department of Microbiology. Chiang Mai, Thailand / La Jolla Institute for Immunology. Center for Vaccine Innovation. San Diego, CA, USA. | |
| Affilliation | La Jolla Institute for Immunology. Center for Vaccine Innovation. San Diego, CA, USA. | |
| Affilliation | La Jolla Institute for Immunology. Center for Vaccine Innovation. San Diego, CA, USA. | |
| Affilliation | La Jolla Institute for Immunology. Center for Vaccine Innovation. San Diego, CA, USA. | |
| Affilliation | La Jolla Institute for Immunology. Center for Vaccine Innovation. San Diego, CA, USA. | |
| Affilliation | La Jolla Institute for Immunology. Center for Vaccine Innovation. San Diego, CA, USA. | |
| Affilliation | La Jolla Institute for Immunology. Center for Vaccine Innovation. San Diego, CA, USA. | |
| Affilliation | La Jolla Institute for Immunology. Center for Vaccine Innovation. San Diego, CA, USA. | |
| Affilliation | La Jolla Institute for Immunology. Center for Vaccine Innovation. San Diego, CA, USA. | |
| Affilliation | University Cardenal Herrera. Valencia, Spain / La Jolla Institute for Immunology. Center for Vaccine Innovation. San Diego, CA, USA. | |
| Affilliation | La Jolla Institute for Immunology. Center for Vaccine Innovation. San Diego, CA, USA / La Jolla Institute for Immunology. Microscopy and Histology Core Facility. San Diego, CA, USA. | |
| Affilliation | La Jolla Institute for Immunology. Center for Vaccine Innovation. San Diego, CA, USA. | |
| Affilliation | La Jolla Institute for Immunology. Center for Vaccine Innovation. San Diego, CA, USA / University of California San Diego. Division of Infectious Diseases and Global Public Health. Department of Medicine. San Diego, CA, USA. | |
| Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Biotecnologia e Fisiologia de Infecções Virais. Rio de Janeiro, RJ, Brasil. | |
| Affilliation | La Jolla Institute for Immunology. Center for Vaccine Innovation. San Diego, CA, USA. | |
| Affilliation | La Jolla Institute for Immunology. Center for Vaccine Innovation. San Diego, CA, USA / University of California San Diego. Division of Host-Microbe Systems and Therapeutics. Department of Pediatrics. San Diego, CA, USA. | |
| Subject | Biotechnology | en_US |
| Subject | Vaccines | en_US |
| e-ISSN | 2059-0105 | |
| xmlui.metadata.dc.subject.ods | 03 Saúde e Bem-Estar | |
| xmlui.metadata.dc.subject.ods | 09 Indústria, inovação e infraestrutura | |
| xmlui.metadata.dc.subject.ods | 17 Parcerias e meios de implementação | |
